NYSEAMERICAN:PTN Palatin Technologies (PTN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PTN Stock Alerts $1.75 +0.03 (+1.74%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$1.70▼$1.8450-Day Range N/A52-Week Range$1.43▼$5.65Volume140,547 shsAverage Volume631,364 shsMarket Capitalization$28.25 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Palatin Technologies alerts: Email Address Palatin Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside849.1% Upside$17.00 Price TargetShort InterestBearish9.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$23,400 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.36) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.45% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palatin Technologies has recently increased by 0.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Palatin Technologies this week, compared to 2 articles on an average week.Search InterestOnly 22 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have sold 83.96% more of their company's stock than they have bought. Specifically, they have bought $12,720.00 in company stock and sold $23,400.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 11.50% of the stock of Palatin Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Palatin Technologies are expected to grow in the coming year, from ($2.36) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalatin Technologies has a P/B Ratio of 179.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Palatin Technologies Stock (NYSEAMERICAN:PTN)Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.Read More PTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTN Stock News HeadlinesApril 12, 2024 | insidertrades.comPalatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Purchases $12,720.00 in StockApril 19, 2024 | americanbankingnews.comPalatin Technologies (NYSEAMERICAN:PTN) Stock Price Crosses Above 200 Day Moving Average of $0.00April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 14, 2024 | americanbankingnews.comPalatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Buys $12,720.00 in StockApril 12, 2024 | msn.comPalatin Technologies And 2 Other Stocks Under $3 Insiders Are BuyingApril 8, 2024 | marketwatch.comPalatin Technologies Shares Rise 27% After Positive Trial Results for PL9643April 8, 2024 | finance.yahoo.comPalatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study DataApril 8, 2024 | msn.comGalectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare moversApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 8, 2024 | msn.comPalatin stock jumps 16% on positive Phase 3 data for eye drugApril 8, 2024 | markets.businessinsider.comPalatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease PositiveApril 8, 2024 | finance.yahoo.comPalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024March 15, 2024 | finance.yahoo.comPTN Apr 2024 2.500 putMarch 15, 2024 | finance.yahoo.comPTN Apr 2024 7.500 callMarch 14, 2024 | msn.comPalatin files to sell 1.92M shares of common stock for holdersFebruary 29, 2024 | markets.businessinsider.comMaintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future ProspectsFebruary 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)February 28, 2024 | msn.comPalatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock PlummetsFebruary 28, 2024 | finanznachrichten.dePalatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 28, 2024 | marketwatch.comPalatin Technologies Shares Tumble Premarket on Dry-Eye Study ResultsFebruary 28, 2024 | finance.yahoo.comPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 28, 2024 | prnewswire.comPalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)February 21, 2024 | finance.yahoo.comPalatin Technologies, Inc. (PTN)February 16, 2024 | markets.businessinsider.comBuy Rating Affirmed on Palatin Technologies for Promising Pipeline and Strategic Market PositioningFebruary 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Palatin Technologies Amid Promising Clinical Trials and Robust Financial PositionFebruary 16, 2024 | finance.yahoo.comPalatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call TranscriptSee More Headlines Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees34Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$17.00 Low Stock Price Target$17.00 Potential Upside/Downside+885.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,540,000.00 Net Margins-445.12% Pretax Margin-503.33% Return on Equity-583.06% Return on Assets-184.90% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$4.85 million Price / Sales5.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book172.50Miscellaneous Outstanding Shares16,140,000Free Float14,894,000Market Cap$27.84 million OptionableNot Optionable Beta0.93 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Carl Spana Ph.D. (Age 62)Co-Founder, President, CEO & Director Comp: $979kMr. Stephen T. Wills CPA (Age 67)MST, CFO, COO, Executive VP, Treasurer & Secretary Comp: $910.55kBurns McClellanVice President of Investor RelationsMr. Stephen A. Slusher Esq.Chief Legal OfficerDr. Michael B. Raizman M.D.Chief Medical OfficerMr. James E. Hattersley (Age 64)Senior Vice President of Business Development Mr. John Dodd Ph.D.Senior Vice President of Preclinical DevelopmentMr. Robert JordanSenior Vice President of Program OperationsMore ExecutivesKey CompetitorsAcasti PharmaNASDAQ:ACSTFreeline TherapeuticsNASDAQ:FRLNLianBioNASDAQ:LIANLipocineNASDAQ:LPCNStarpharmaOTCMKTS:SPHRYView All CompetitorsInsiders & InstitutionsRobert K Deveer JrBought 6,000 shares on 4/11/2024Total: $12,720.00 ($2.12/share)Robert K Deveer JrSold 11,700 sharesTotal: $23,400.00 ($2.00/share)Armistice Capital LLCBought 590,000 shares on 2/13/2024Ownership: 4.294%Stephen T WillsSold 4,998 sharesTotal: $12,544.98 ($2.51/share)Alan W DuntonSold 200 sharesTotal: $496.00 ($2.48/share)View All Insider TransactionsView All Institutional Transactions PTN Stock Analysis - Frequently Asked Questions Should I buy or sell Palatin Technologies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks. What is Palatin Technologies' stock price target for 2024? 1 brokerages have issued twelve-month price targets for Palatin Technologies' shares. Their PTN share price targets range from $17.00 to $17.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 849.1% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts. How have PTN shares performed in 2024? Palatin Technologies' stock was trading at $4.00 at the beginning of the year. Since then, PTN shares have decreased by 55.2% and is now trading at $1.7912. View the best growth stocks for 2024 here. Are investors shorting Palatin Technologies? Palatin Technologies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 25.0% from the February 29th total of 1,160,000 shares. Based on an average daily volume of 552,700 shares, the days-to-cover ratio is presently 2.6 days. Approximately 9.4% of the shares of the stock are sold short. View Palatin Technologies' Short Interest. When is Palatin Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PTN earnings forecast. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to the consensus estimate of $2.28 million. Palatin Technologies had a negative trailing twelve-month return on equity of 583.06% and a negative net margin of 445.12%. During the same quarter last year, the company posted ($0.13) earnings per share. When did Palatin Technologies' stock split? Palatin Technologies's stock reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:PTN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
